Levels of N-linked glycosylation on th V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates

Current HIV Research

Volumn 6, Issue 4, 2008, Pages 296-305

  Huang, Zuhu ^a,b   Chou, Arthur ^c   Tanguay, Jonathan ^b   Shen, Siyuan ^b   Mboudjeka, Innocent ^b   Chou, Te Hui ^b   Lu, Shan ^a,b   Wang, Shixia ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c CLARK UNIVERSITY   (United States)

Author keywords

Antigenicity; Env; HIV 1; N linked glocosylation sites; V1 loop

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGENICITY; BIOINFORMATICS; CLADISTICS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE GUN IMMUNIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; RABBIT; REVIEW; TREATMENT OUTCOME; VIRUS ISOLATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIGENIC VARIATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GLYCOSYLATION; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES, DNA;

EID: 52449127095     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785132518     Document Type: Review

References (56)

1. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/ (H5N1) Reported to WHO. 2007 [date accessed June 4, 2007]; Available from: http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2007_05_31/en/index.html
2. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004;10(8): 806-10.
3. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med 2004; 10(8): 769-71.
4. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292(5514): 69-74.
5. Barouch DH, Santra S, Schmitz JE, et al. Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augumented DNA Vaccination. Science 2000; 290: 486-92.
6. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adeno-viral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415(6869): 331-5.
7. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007; 318(5853): 1048-9.
8. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422(6929): 307-12.
9. Smith TF, Srinivasan A, Schochetman G, Marcus M, Myers G. The phylogenetic history of immunodeficiency viruses. Nature 1988; 333(6173): 573-5.
10. Kostrikis LG, Bagdades E, Cao Y, Zhang L, Dimitriou D, Ho DD. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J Virol 1995; 69(10): 6122-30.
11. Leitner T, Escanilla D, Marquina S, et al. Biological and molecular characterization of subtype D, G, and A/D recombinant HIV-1 transmissions in Sweden. Virology 1995; 209(1): 136-46.
12. Louwagie J, Janssens W, Mascola J, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol 1995; 69(l): 263-71.
13. Li WH, Tanimura M, Sharp PM. Rates and dates of divergence between AIDS virus nucleotide sequences. Mol Biol Evol 1988; 5(4): 313-30.
14. Korber B, Wolinsky S, Haynes B, et al. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res Hum Retroviruses 1992; 8(8): 1461-5.
15. Janssens W, Heyndrickx L, Fransen K, et al. Genetic and phylogenetic analysis of env subtypes G and H in central Africa. AIDS Res Hum Retroviruses 1994; 10(7): 877-9.
16. Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994; 68(3): 1581-5.
17. Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4(9): 1032-7.
18. Gao F, Morrison SG, Robertson DL, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol 1996; 70(3): 1651-67.
19. Mboudjeka I, Bikandou B, Zekeng L, et al. Genetic diversity of HIV- group M from Cameroon and Republic of Congo. Arch Virol 1999; 144(12): 2291-311.
20. Nkengasong JN, Janssens W, Heyndrickx L, et al. Genotypic subtypes of HIV-1 in Cameroon. AIDS 1994; 8(10): 1405-12.
21. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol 2000; 74(22): 10498-507.
22. Ackers ML, Parekh B, Evans TG, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 2003; 187(6): 879-86.
23. Burton DR, Stanfield RL, Wilson IA. Antibody vs HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 2005; 102(42): 14943-8.
24. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998; 4(6): 679-84.
25. Reitter JN, Desrosiers RC. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol 1998; 72(7): 5399-407.
26. Lu S, Wyatt R, Richmond JF, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14(2): 151-5.
27. Moore JP, Sattentau QJ, Wyatt R, Sodroski J. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994; 68(1): 469-84.
28. Sanders RW, Schiffner L, Master A, et al. Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits. J Virol 2000; 74(11): 5091-100.
29. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp 120 epitopes induced by receptor binding. J Virol 1995; 69(9): 5723-33.
30. Wyatt R, Sullivan N, Thali M, et al. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993; 67(8): 4557-65.
31. Cherpelis S, Jin X, Gettie A, et al. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol Lett 2001; 79(1-2): 47-55.
32. Cherpelis S, Shrivastava I, Gettie A, et al. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques. J Virol 2001; 75(3): 1547-50.
33. Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001; 75(12): 5526-40.
34. Lu S. Developing DNA vaccines against immunodeficiency viruses. Curr Top Microbiol Immunol 1998; 226: 161-73.
35. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 1997; 9(5): 271-83.
36. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90(18): 8392-6.
37. Wang S, Joshi S, Lu S. Delivery of DNA to Skin by Particle Bombardment. In: Heiser WC, ed. Gene Delivery to Mammalian Cells: Humana Press 2004.
38. Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. In: Lowrie DaW, R, Ed. Methods in Molecular Medicine DNA Vaccines: Humana Press 1999: 355-74.
39. Wang S, Pal R, Mascola JR, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from sub-types A, B, C, D and E. Virology 2006; 350(1): 34-47.
40. Moore JP, McCutchan FE, Poon SW, et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994; 68(12): 8350-64.
41. Cheingsong-Popov R, Osmanov S, Pau CP, et al. Serotyping of HIV type 1 infections: definition, relationship to viral genetic sub-types, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization. AIDS Res Hum Retroviruses 1998; 14(4): 311-8.
42. Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 2005; 79(11): 6909-17.
43. Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 1993; 67(6): 3649-52.
44. Carrillo A, Ratner L. Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 1996; 70(2): 1310-6.
45. Gram GJ, Hemming A, Bolmstedt A, et al. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch Virol 1994; 139(3-4): 253-61.
46. Part IV. HIV Monoclonal Antibodies. Los Alamos National Laboratory. HIV Molecular Immunology Compendium 2001 [accessed March 25, 2008] Available from: http://www.hiv.lanl.gov/content/immunology/contents2000.html.
47. Cao J, Sullivan N, Desjardin E, et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997; 71(12): 9808-12.
48. Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997; 71(10): 7719-27.
49. Polacino P, Stallard V, Montefiori DC, et al. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J Virol 1999; 73(4): 3134-46.
50. Polacino P, Stallard V, Klaniecki JE, et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 1999; 73(1): 618-30.
51. Mascola JR, Montefiori DC. HIV-1: nature's master of disguise. Nat Med 2003; 9(4): 393-4.
52. Morris L. Neutralizing antibody responses to HIV-1 infection. IUBMB Life 2002; 53(4-5): 197-9.
53. Wang S, Arthos J, Lawrence JM, et al. Enhanced inummogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005; 79(12): 7933-7.
54. Beddows S, Schulke N, Kirschner M, et al. Evaluating the immunogenicity of a disulfide- stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005; 79(14): 8812-27.
55. Law M, Cardoso RM, Wilson IA, Burton DR. Antigenic and Immunogenic Study of Membrane-Proximal External Region-Grafted gp120 Antigens by a DNA Prime-Protein Boost Immunization Strategy. J Virol 2007; 81(8): 4272-85.
56. Wang S, Kennedy J, West K, et al. Balanced cellular and antibody responses induced by the polyvalent DNA prime-protein boost HIV-1 vaccine formulation DP6-001 in healthy human volunteers. Vaccine 2008; 26: 1098-110.